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Abstract
Intracellular accumulation of toxic, hydrophobic bile acids has been proposed as one of the putative final common pathways leading to
cholestatic liver injury. Furthermore, bile acids have been proposed as a causative factor for hepatic cardiomyopathy. Hepatic tissue
concentrations of chenodeoxycholic acid (CDCA) during cholestasis are greater than those of other toxic bile acids. In the presence of
calcium and phosphate, CDCA induced the permeability transition pore (PTP) in freshly isolated rat liver mitochondria. In this study, we
evaluated the effects of carvedilol, a multirole cardioprotective compound, on CDCA-induced PTP. Mitochondrial membrane potential,
osmotic swelling, and calcium fluxes were monitored. CDCA-induced PTP, characterized by membrane depolarization, release of matrix
calcium, and osmotic swelling, was prevented by carvedilol. Under the same conditions, its hydroxylated analog BM-910228 did not reveal
any protective effect. This finding reinforces carvedilol’s therapeutic interest, because it may potentially prevent mitochondrial dysfunction
associated with cardiomyopathy in the pathophysiology of cholestatic liver disease. © 2001 Elsevier Science Inc. All rights reserved.
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1. Introduction
Cholestasis, an arrest or stagnation in bile flow, is one
type of liver disease of unknown etiology. There are a
variety of possible causes, but one of the putative final
common pathways leading to cholestatic liver injury is the
intracellular accumulation of bile acids [1,2]. Bile acids, the
water-soluble, amphipathic end products of cholesterol me-
tabolism, are involved in liver, biliary, and intestinal disease
[3]. These compounds have the capacity to induce both
choleresis and cholestasis, depending on the concentrations
and hydrophobic properties of individual bile acids [4,5].
Chenodeoxycholic acid is a primary bile acid mostly impli-
cated in liver injury. Hepatic tissue concentrations of CDCA
increase 20-fold during cholestasis and are greater than
those of other toxic bile acids such as lithocholate (LCA)
and deoxycholate (DCA) [6].
In a number of studies, impairment of mitochondrial
function has been proposed as a cause of hepatocyte dys-
function leading to cholestatic liver injury [7–11]. The ma-
jor function of mitochondria in human cells is to provide
ATP by oxidative phosphorylation. However, mitochondria
have many other roles, including the modulation of intra-
cellular calcium concentration and participation in the pro-
cess of apoptotic cell death [12]. Consequently, mitochon-
drial dysfunction contributes to a great number of human
diseases [13].
Recent data pointed out induction of the PTP as a mech-
anism of cytotoxicity of bile acids [11,14,15]. Mitochon-
drial permeability transition is a calcium-dependent process
linked to the opening of a non-specific channel into the
inner membrane. The mitochondrial PTP is normally ac-
companied by mitochondrial swelling, a precipitous drop in
membrane potential (DC), and the spontaneous release of
accumulated calcium [16] and other gradients. This phe-
nomenon is stimulated by the presence of inorganic phos-
phate, oxidative stress, or dithiol reagents [16–19], and is
typically inhibited by cyclosporine A [20]. PTP activation is
voltage-dependent, i.e. opening is facilitated by depolariza-
tion [17,21], and is now recognized to be closely involved in
cell death either by necrosis or by apoptosis [22].
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A possible relationship between plasma accumulation of
bile acids and the cardiomyopathy of cholestatic liver dis-
ease has been proposed [23]. A recent report indicates that
bile acid-induced modification of cardiac b-adrenoreceptor
activity may represent a mechanism whereby these com-
pounds exert their effects on cardiac performance [24].
Carvedilol ({1-[carbazolyl-(4)-oxy]-3-[2-methoxyphenoxy-
ethyl)amino]-propanol-(2)}) is a lipophilic, vasodilating
b-adrenoreceptor blocking agent with known cardioprotec-
tive properties. Among the various metabolites of carve-
dilol, BM-910228 ({1-[3 hydroxycarbazolyl-(4)-oxy]-3-[2-
methoxyphenoxyethyl)amino]-propanol-(2)}) is one of the
most important.
Although there are still considerable uncertainties about
the mechanisms underlying the multiple cardioprotective
effects of carvedilol, its action could be related to protection
of mitochondrial function. Thus, it is reasonable to hypoth-
esize that carvedilol may potentially prevent bile acid-in-
duced mitochondrial dysfunction.
The aim of this study was to investigate the in vitro
effects of carvedilol and its metabolite BM-910228 on the
CDCA-induced PTP in rat liver mitochondria. Within this
context, mitochondrial swelling, membrane potential, and
mitochondrial calcium fluxes were monitored.
2. Materials and methods
2.1. Chemicals
CDCA, used as ethanolic solution, was purchased from
Sigma Chemical Co. Carvedilol and BM-910228 were ob-
tained from Boehringer. All other chemicals were of the
highest grade of purity commercially available.
2.2. Isolation of mitochondria
Mitochondria were isolated from liver of male Wistar
rats by conventional methods [25] with slight modifications.
Homogenization medium contained 250 mM sucrose, 10
mM HEPES (pH 7.4), 0.5 mM EGTA, and 0.1% fat-free
BSA. EGTA and BSA were omitted from the final washing
medium, adjusted at pH 7.4. The mitochondrial pellet was
washed twice, suspended in the washing medium, and im-
mediately used. Protein content was determined by the
biuret method [26] calibrated with BSA.
2.3. Membrane potential measurements
The mitochondrial transmembrane potential was esti-
mated using an ion-selective electrode to measure the dis-
tribution of TPP1 according to previously established meth-
ods [27,28]. The reference electrode was Ag/AgCl2. The
incubation medium contained 200 mM sucrose, 10 mM
Tris–Mops (3-[N-morpholino]propanesulfonic acid) (pH
7.4), 1 mM KH2PO4, and 10 mM EGTA supplemented with
2 mM rotenone and 0.5 mg/mL of oligomycin. Mitochondria
(0.5 mg) were suspended with constant stirring, at 25°, in 1
mL of the standard incubation medium supplemented with 3
mM TPP1 and energized by adding succinate to a final
concentration of 5 mM. The distribution of TPP1 was
allowed to reach a new equilibrium (ca. 2 min) before
making any further addition. The electrode was calibrated
with TPP1 assuming Nerstian distribution of the ion across
the synthetic membrane. A matrix volume of 1.1 mL/mg of
protein was assumed.
2.4. Measurement of mitochondrial permeability transition
Mitochondrial swelling was estimated by changes in
light scattering as monitored spectrophotometrically at 540
nm [29]. The reaction medium was stirred continuously and
the temperature maintained at 25°. The experiments were
started by the addition of 1 mg of mitochondria to a final
volume of 2 mL of the standard incubation medium, sup-
plemented with 2 mM rotenone, 0.5 mg/mL of oligomycin,
and 5 mM succinate. Calcium (50 mM CaCl2) was added
prior to all the other compounds.
2.5. Measurement of mitochondrial calcium fluxes
The accumulation and release of calcium by isolated rat
liver mitochondria was determined using a calcium-sensi-
tive fluorescent dye, calcium green-5N [30]. The reactions
were carried out at 25°, in 2 mL of the standard incubation
medium, supplemented with 2 mM rotenone, 0.5 mg/mL of
oligomycin, and 0.1 mM calcium green-5N. Mitochondria
(0.4 mg) were suspended with constant stirring. Fluores-
cence (excitation 505 nm; emission 531 nm) was monitored
continuously for an additional 1.5 min prior to adding cal-
cium (CaCl2) to a final concentration of 15 mM. Fluores-
cence was monitored continuously for an additional 3 min,
at which time 8 mM succinate was added to the suspension.
At each experiment, fluorescence was monitored for an
additional 10 min before the reaction was stopped with
excess EGTA. Calcium fluxes are expressed as relative
fluorescence units (RFU). At the concentration examined,
CDCA did not interfere with the experimental assay.
3. Results
3.1. Effect of CDCA on mitochondrial membrane
potential
Fig. 1 reports DC dissipation caused by CDCA (50 mM)
in succinate-energized, isolated rat liver mitochondria. In
the presence of calcium (50 mM), mitochondria depolarized
immediately upon addition of CDCA, and resting mem-
brane potential was never restored. Such changes are char-
acteristic of an increased permeability of the mitochondrial
inner membrane. To ascertain whether the decrease could be
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attributed to the PTP, we treated the mitochondria with
CyA. Under these conditions, mitochondria were able of
sustaining membrane potential after the addition of CDCA.
A similar result was observed for carvedilol (10 mM). In-
deed, after preincubation with carvedilol, and upon addition
of CDCA to calcium-loaded mitochondria, an immediate
depolarization of membrane potential occurred, but it was
incomplete and DC remained stable within the time moni-
tored. In contrast, in the presence of BM-910228 and upon
addition of CDCA, mitochondria were not capable of main-
taining membrane potential, and a complete dissipation was
observed. Control experiments showed that carvedilol alone
induced a slight decrease in DC (Fig. 1). Additionally, its
hydroxylated analog, BM-910228, had a similar behavior
only for higher concentrations than that used for carvedilol
(data not shown).
3.2. Effect of CDCA on calcium-dependent mitochondrial
swelling
In order to support the suggestion of the protective ef-
fects of carvedilol on the induction of permeability transi-
tion by CDCA, we performed swelling experiments. Succi-
nate-energized, hepatic mitochondria underwent a large-
amplitude decrease in light scattering (Fig. 2) upon addition
of CDCA. This CDCA-induced mitochondrial swelling re-
quired mitochondria preloaded with calcium (data not
shown). No swelling was observed in the control experi-
ment following calcium addition (Fig. 2), showing that
mitochondria loaded with 50 mM calcium maintained their
permeability barrier. The fact that the CDCA-induced de-
crease in absorbance was inhibited by cyclosporine A indi-
cates that this was the result of the calcium-dependent PTP
induction. Additionally, CDCA-induced mitochondrial
swelling was strongly prevented by pretreating mitochon-
dria in vitro with 10 mM carvedilol, which is what would be
predicted from the results of the membrane potential exper-
iments. In contrast, BM-910228 had no effect on the mito-
chondrial response to CDCA addition (Fig. 2). Control
experiments were designed to assess if addition of carve-
dilol (Fig. 2) or BM-910228 (not shown) to hepatic mito-
chondria induces changes in absorbance. There was no
discernible difference in the trace compared to that of the
control sample.
3.3. Effect of CDCA on mitochondrial calcium release
The experiment reported in Fig. 3 shows the ability of
CDCA to induce mitochondrial calcium efflux. Measure-
ment of calcium fluxes indicated that unlike control mito-
chondria (which accumulated all of the added calcium and
retained it for the entire period monitored), addition of
CDCA induced release of matrix calcium. The disturbing
action of CDCA on mitochondrial calcium homeostasis was
partially prevented by carvedilol, whereas BM-910228 had
no significant effect (Fig. 3). Control experiments showed
no interference with calcium fluxes when BM-910228 (data
not shown) or carvedilol (Fig. 3) was added to calcium-
loaded, succinate-energized mitochondria.
4. Discussion
The plasma accumulation of bile acids has been pro-
posed by several investigators as a causative factor for
hepatic cardiomyopathy [23]. However, the mechanism
whereby bile acids exert these cardiac effects is unclear.
Mitochondrial dysfunction is central to a range of important
human disorders. In order to treat these disorders and de-
velop mitochondrial medicine, the enhancement of the abil-
ity to manipulate mitochondrial function is essential to pro-
tect against mitochondrial damage in rational ways.
The observation that CDCA, a primary bile acid, in-
creases the sensitivity of isolated mitochondria to calcium-
dependent induction of the PTP provides a physicochemical
explanation for the bioenergetic form of cell death caused
by toxic bile acids. Classically, PTP opening has been
associated with generalized mitochondrial dysfunction,
which is consistent with a role of the PTP in cell death. This
phenomenon is implicated in the mechanism of cell killing
by a number of agents, including heavy metals, pesticides,
Fig. 1. Effects on membrane potential (DC) of mitochondria energized
with succinate. Mitochondria (0.5 mg) were incubated in 1 mL of the
standard incubation medium supplemented with 2 mM rotenone, 0.5
mg/mL of oligomycin, and 3 mM TPP1, and energized with 5 mM succi-
nate. Calcium was added at a final concentration of 50 mM. When indi-
cated, 1 mM CyA, 10 mM carvedilol (Carv), or 10 mM BM-910228 was
included in the reaction medium prior to addition of 50 mM CDCA. The
traces are typical of several independent experiments with four different
mitochondrial preparations.
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and selected pharmaceuticals [21,31]. Mitochondrial perme-
ability transition is due to the formation of a non-specific
pore in the inner membrane which renders it permeable to
solutes smaller than about 1.5 kDa, including H1, thus
uncoupling electron transport from oxidative phosphoryla-
tion [16]. The structure of the pore is still not certain, but is
thought to be a supramolecular complex comprising pro-
teins of the matrix (cyclophilin D), of the inner (adenine
nucleotide translocator) and outer (voltage-dependent anion
channel, perhaps Bax) mitochondrial membranes, and of the
periplasmic space (creatine kinase) [16,32]. Such a complex
constitution of the pore is reflected by the multitude of
regulatory factors that influence the open/closed probability
of the pore [16].
Carvedilol, a multiple-action neurohormonal antagonist
with known cardioprotective effects, has been previously
described [33] as a specific inhibitor of endogenous NADH
dehydrogenase in heart mitochondria. In this study, the
measurements of light scattering, membrane potential, and
calcium movements indicated that carvedilol prevents
CDCA-induced PTP. The effect of many inducers or inhib-
itors of the PTP may actually consist in a modulation of the
“sensitivity” of the pore to voltage [17,21,31]. Due to its
protonophoric effect [34], carvedilol and, to a lesser extent
its metabolite BM-910228, caused a direct and slight depo-
larization of membrane potential, which by itself was insuf-
ficient to cause the PTP. A possible mechanism whereby
carvedilol would be effective at preventing induction of the
mitochondrial PTP could be attributed to a successful com-
petition (with CDCA) for a specific voltage-sensing element
that could be responsible for the induced shift in gating
potential of the PTP. The demonstrated different action of
carvedilol and BM-910228 against the induction of perme-
ability transition by CDCA did not confirm the proposed
interaction with the voltage-sensing element of the PTP.
The mechanism by which bile acids promote the onset of
the PTP remains unclear. It is known that oxidative stress
or, in general, oxidizing conditions appear to act as inducers
of the PTP [16]. It has been suggested [10,35,36] that
oxygen free radicals may be involved in the pathogenesis of
bile acid toxicity by causing increased leaking from the
altered electron transport chain. It is proposed that a critical
factor regulating induction of the PTP is the oxidation state
of cysteine residues in the immediate vicinity of the voltage-
sensing element of the pore [37]. Thus, the reported bene-
ficial effects of carvedilol could be due to its potent antiox-
idant activity [38] in interfering with a hypothetical
oxidative mechanism of induction of permeability transition
by CDCA. By contrast, BM-910228 (shown to have higher
antioxidant activity than carvedilol [39]) did not afford
protection against CDCA-induced membrane depolariza-
tion, mitochondrial swelling, or matrix calcium release, the
antioxidant effect of carvedilol not being valid to justify this
result.
The hypothesis of a direct interaction with the pore
assembly could also explain the action of carvedilol in
Fig. 2. Effects on mitochondrial swelling. The incubation medium (final volume 2 mL at 25°) contained 200 mM sucrose, 10 mM Tris–Mops (pH 7.4), 1
mM KH2PO4, and 10 mM EGTA supplemented with 2 mM rotenone, 0.5 mg/mL of oligomycin, and 5 mM succinate. The experiments were started by the
addition of 1 mg of mitochondria (not shown). Calcium (50 mM) was added prior to all other compounds. Where indicated (first arrow), 1 mM CyA, 10 mM
carvedilol (Carv), or 10 mM BM-910228 was included in the reaction medium prior to 50 mM CDCA. The traces are typical of several independent
experiments with four different mitochondrial preparations.
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modulating the ability of CDCA to induce PTP opening.
Due to its great lipophilicity, carvedilol has a considerable
tendency for membrane insertion [40] and may disturb the
correct assemblage of the pore proteic components.
In summary, our data provide strong evidence for pre-
vention by carvedilol against mitochondrial damage in-
duced by the toxic bile acid, chenodeoxycholate. Thus, it is
possible that such protection may modulate the injurious
action of bile acids, providing an alternate means for pro-
tecting cell damage. This new observation with potential
therapeutic interest may provide an important opportunity to
intervene in the clinical management of cholestatic disease
and its associated cardiomyopathy.
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